Industry
Biotechnology
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
August 15, 2024 | 2:22 pm
Portfolio Pulse from Benzinga Insights
August 02, 2024 | 1:00 pm
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 12:28 pm
Portfolio Pulse from Benzinga Newsdesk
August 02, 2024 | 12:02 pm
Portfolio Pulse from Benzinga Newsdesk
August 01, 2024 | 8:45 pm
Portfolio Pulse from Avi Kapoor
June 20, 2024 | 12:11 pm
Portfolio Pulse from Benzinga Newsdesk
June 20, 2024 | 10:22 am
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 2:54 pm
Portfolio Pulse from Benzinga Insights
June 14, 2024 | 4:00 pm
Portfolio Pulse from Benzinga Newsdesk
June 14, 2024 | 3:51 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.